Table 2. CD14+ CD16+ (FcγRIII) monocytes/macrophages in the patients with KD during the acute stage and the convalescent stage, and in control subjects.
| KD (n = 28) | ||||
|---|---|---|---|---|
| Acute | Control subjects | |||
| Before IVGG | After IVGG | Convalescent | (n = 20) | |
| Mononuclear cells (cells/µl) | 5271 ± 2705 | 5779 ± 2354 | 5374 ± 2274 | 5585 ± 1783 |
| CD14+CD16+monocytes/macrophages (%) | 3·6 ± 3·5* | 0·6 ± 0·6 | 0·5 ± 0·3 | 0·7 ± 0·3 |
| CD14+CD16+monocytes/macrophages (cells/µl) | 155 ± 132* | 35 ± 32 | 25 ± 18 | ″35 ± 18 |
| Percentage of CD14+CD16+ monocytes/macrophages among CD14+ monocytes/macrophages (%) | 21·6 ± 12·5* | 6·6 ± 6·8 | 6·7 ± 3·7 | 10·1 ± 4·3 |
Values are expressed as mean ± s.d.
*
Significant at P < 0·01 versus convalescent stage and control subjects.